Although it has been previously established that doxycycline inhibits proinflammatory responses by acting via the mTOR pathway in cancer cell lines, its impact on the inflammasome pathway, particularly in the lungs, has not yet been evaluated. The gene discussed is MTOR; the disease is cancer.